EGFR and neoplasm: Compared with either single-agent treatment, combined targeting of MET and EGFR resulted in enhanced reductions in tumour volumes and weights, accompanied by decreased activation of downstream signaling pathways in vivo, and the results were consistent with those of the in vitro experiments.